To this end, the decoy receptor 3 (DcR3), which counteracts CD95-mediated apoptosis by competitively binding CD95 ligand, was shown to be overexpressed in lung carcinoma or colon carcinoma and in glioblastoma [25, 26] and TRAIL-R3; a decoy receptor for TRAIL was reported to be expressed at high levels in gastric carcinoma [27]. This evidence concerns the gene TNFRSF6B and colon carcinoma.